Recurrent Melanoma

Check It Out: May is Skin Cancer Awareness Month (05-1-2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (11-9-2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (05-1-2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

Coffee May Decrease Risk of Melanoma Skin Cancer (02-2-2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (12-23-2014)

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (12-8-2014)

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR) 2014 International... Continue Reading

Injecting of PV-10 is Promising Treatment of Melanoma Lesions (11-25-2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures (11-24-2014)

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy... Continue Reading

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (11-20-2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (11-19-2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

Next Page »